Medical Marijuana, Inc. Portfolio Company Kannalife Announces Completion of Name Change, Ticker Symbol Change

SAN DIEGO, Jan. 17, 2019 /PRNewswire/ -- Medical Marijuana, Inc. (OTC: MJNA), the first-ever publicly traded cannabis company in the United States, announced today that its portfolio company KannaLife, Inc. ("Kannalife") (OTC: KLFE), a bio-pharmaceutical and phyto-medical company, has announced the company's name change from TYG Solutions Corp. to Kannalife, Inc. and the change of ticker symbol to "KLFE." These changes have been reviewed and processed by the Financial Industry Regulatory Authority (FINRA).

The name and ticker symbol change became effective at the opening of trading today, January 17, 2019.

"We are thrilled to announce the completion of this name and ticker change," said Medical Marijuana, Inc. CEO Dr. Stuart Titus. "Our company was an early investor in Kannalife and we believe that Kannalife's powerful research and portfolio of IP sets the company apart in an increasingly competitive cannabinoid pharmaceutical market arena."

Dean Petkanas, CEO of Kannalife, stated, "We are excited that the corporate actions have been processed by FINRA. This is one of the first steps in the growth of our status as a public company as we continue our research and development into developing disruptive cannabinoid-based therapeutics for neurodegenerative and oxidative stress-related diseases."

About Kannalife, Inc. – A Phyto-Medical Company™

Kannalife, Inc. is a phyto-medical company involved in the research and development of novel therapeutic agents designed to be neuroprotectants and immuno-modulators. Kannalife is currently conducting research and development at the Pennsylvania Biotechnology Center in Doylestown, PA, for target drug candidates to treat hepatic encephalopathy ("HE"), chronic traumatic encephalopathy ("CTE") and Chemotherapy Induced Peripheral Neuropathy ("CIPN"). HE and CTE are oxidative stress-related diseases that affect cognitive and behavioral functions. CIPN is a neurodegenerative condition that afflicts patients undergoing chemotherapy with symptoms that include numbness, tingling, and pain.
For more information, visit

About Medical Marijuana, Inc.

We are a company of firsts®. Our mission is to be the premier cannabis and hemp industry innovators, leveraging our team of professionals to source, evaluate and purchase value-added companies and products while allowing them to keep their integrity and entrepreneurial spirit. We strive to create awareness within our industry, develop environmentally friendly, economically sustainable businesses, while increasing shareholder value. For details on Medical Marijuana, Inc.'s portfolio and investment companies, visit

To see Medical Marijuana, Inc.'s corporate video, click here.

Shareholders and consumers are also encouraged to buy CBD oil and other products at Medical Marijuana, Inc.'s shop.


This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to be materially different from the statements made herein.


These statements have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease.

Medical Marijuana, Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA). These companies do grow, sell, and distribute hemp-based products and are involved with the federally legal distribution of medical marijuana-based products within certain international markets. Cannabidiol is a natural constituent of hemp oil.

Public Relations Contact:
Andrew Hard
Chief Executive Officer CMW Media
P. 858-264-6600

Cision View original content:

SOURCE Medical Marijuana, Inc.


Back to news